{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:07:12Z","timestamp":1794708432398,"version":"4.9.1"},"reference-count":48,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The dramatic success of tyrosine kinase inhibitors (TKIs) has led to the widespread perception that chronic myeloid leukemia (CML) has become another chronic disease, where lifelong commitment to pharmacologic control is the paradigm. Recent trials demonstrate that some CML patients who have achieved stable deep molecular response can safely cease their therapy without relapsing (treatment free remission [TFR]). Furthermore, those who are unsuccessful in their cessation attempt can safely re-establish remission after restarting their TKI therapy. Based on the accumulated data on TFR, we propose that it is now time to change our approach for the many CML patients who have achieved a stable deep molecular response on long-term TKI therapy. Perhaps half of these patients could successfully achieve TFR if offered the opportunity. For many of these patients ongoing therapy is impairing quality of life and imposing a heavy financial burden while arguably achieving nothing. This recommendation is based on the evident safety of cessation attempts and TFR in the clinical trial setting. We acknowledge that there are potential risks associated with cessation attempts in wider clinical practice, but this should not deter us. Instead we need to establish criteria for safe and appropriate TKI cessation. Clinical trials will enable us to define the best strategies to achieve TFR, but clinicians need guidance today about how to approach this issue with their patients. We outline circumstances in which it would be in the patient's best interest to continue TKI, as well as criteria for a safe TFR attempt.<\/jats:p>","DOI":"10.1182\/blood-2016-01-694265","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T23:16:05Z","timestamp":1458861365000},"page":"17-23","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":274,"title":["Moving treatment-free remission into mainstream clinical practice in CML"],"prefix":"10.1182","volume":"128","author":[{"given":"Timothy P.","family":"Hughes","sequence":"first","affiliation":[{"name":"Haematology, SA Pathology, School of Medicine, University of Adelaide, Adelaide, Australia; and South Australian Health & Medical Research Institute, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Ross","sequence":"additional","affiliation":[{"name":"Haematology, SA Pathology, School of Medicine, University of Adelaide, Adelaide, Australia; and South Australian Health & Medical Research Institute, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"14","key":"2019111902354567700_B1","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1002\/cncr.28106","article-title":"Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.","volume":"119","author":"Brunner","year":"2013","journal-title":"Cancer"},{"issue":"5","key":"2019111902354567700_B2","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"issue":"1","key":"2019111902354567700_B3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1756-8722-6-70","article-title":"Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century.","volume":"6","author":"Pulte","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2019111902354567700_B4","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"2019111902354567700_B5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111902354567700_B6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2404139","article-title":"Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.","volume":"20","author":"Ross","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"2019111902354567700_B7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"15","key":"2019111902354567700_B8","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111902354567700_B9","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","article-title":"BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111902354567700_B10","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"2019111902354567700_B11","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111902354567700_B12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2019111902354567700_B13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","article-title":"Measuring the symptom burden associated with the treatment of chronic myeloid leukemia.","volume":"122","author":"Williams","year":"2013","journal-title":"Blood"},{"issue":"17","key":"2019111902354567700_B14","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111902354567700_B15","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"2019111902354567700_B16","article-title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis [published online ahead of print October 20, 2015].","author":"Chai-Adisaksopha","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2019111902354567700_B17","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1002\/cncr.29587","article-title":"Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.","volume":"121","author":"Yilmaz","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"2019111902354567700_B18","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1182\/blood.V79.8.1920.1920","article-title":"Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy.","volume":"79","author":"Lee","year":"1992","journal-title":"Blood"},{"issue":"1","key":"2019111902354567700_B19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2002.20.1.214","article-title":"Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa.","volume":"20","author":"Mahon","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111902354567700_B20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111902354567700_B21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111902354567700_B22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111902354567700_B23","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1182\/blood-2011-11-393041","article-title":"BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management.","volume":"119","author":"Branford","year":"2012","journal-title":"Blood"},{"key":"2019111902354567700_B24","author":"Mahon"},{"key":"2019111902354567700_B25","author":"Lee"},{"issue":"21","key":"2019111902354567700_B26","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.654.654","article-title":"Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib [abstract].","volume":"122","author":"Mahon","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111902354567700_B27","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"key":"2019111902354567700_B28","author":"Rea"},{"issue":"6","key":"2019111902354567700_B29","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.","volume":"97","author":"Takahashi","year":"2012","journal-title":"Haematologica"},{"key":"2019111902354567700_B30","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3109\/10428194.2013.831092","article-title":"Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.","volume":"55","author":"Benjamini","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111902354567700_B31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.leukres.2012.02.011","article-title":"Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.","volume":"36","author":"Yhim","year":"2012","journal-title":"Leuk Res"},{"issue":"15","key":"2019111902354567700_B32","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).","volume":"49","author":"Thielen","year":"2013","journal-title":"Eur J Cancer"},{"issue":"25","key":"2019111902354567700_B33","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111902354567700_B34","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.leukres.2015.07.004","article-title":"Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.","volume":"39","author":"Breccia","year":"2015","journal-title":"Leuk Res"},{"issue":"2","key":"2019111902354567700_B35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjh.13103","article-title":"Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia.","volume":"168","author":"Giona","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111902354567700_B36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pbc.24521","article-title":"Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase.","volume":"61","author":"Millot","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2019111902354567700_B37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2019111902354567700_B38","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","article-title":"Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.","volume":"28","author":"Goldman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111902354567700_B39","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"26","key":"2019111902354567700_B40","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111902354567700_B41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111902354567700_B42","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood-2012-02-408229","article-title":"Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response.","volume":"120","author":"Legros","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111902354567700_B43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.812.812","article-title":"Early disease relapse after tyrosine kinase inhibitor treatment discontinuation in CML is related both to low number and impaired function of NK-cells chronic myeloid leukemia: therapy [abstract].","volume":"124","author":"Ilander","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111902354567700_B44","article-title":"Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years: preliminary results from Immunostim, on behalf of STIM Investigators [abstract].","volume":"122","author":"Rea","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2019111902354567700_B45","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111902354567700_B46","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111902354567700_B47","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jmoldx.2015.09.005","article-title":"Next-generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients.","volume":"18","author":"Alikian","year":"2016","journal-title":"J Mol Diagn"},{"key":"2019111902354567700_B48","author":"Latham"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/1\/17\/1395099\/17.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/1\/17\/1395099\/17.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:38:06Z","timestamp":1574131086000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/1\/17\/35341\/Moving-treatmentfree-remission-into-mainstream"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-01-694265","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726236800.793523213","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]}}}